Patents Assigned to Neuropharma, S.A.
-
Patent number: 8686042Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.Type: GrantFiled: July 28, 2006Date of Patent: April 1, 2014Assignee: Neuropharma, S.A.Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
-
Patent number: 8067441Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.Type: GrantFiled: July 28, 2006Date of Patent: November 29, 2011Assignees: Neuropharma, S.A., Instituto Biomar, S.A.Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
-
Publication number: 20100048635Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.Type: ApplicationFiled: July 28, 2006Publication date: February 25, 2010Applicants: Neuropharma, S.A., Instituto Biomar, S.A.Inventors: Ana Martinez Gil, Paola Egea, Miguel Medina Padilla, Esther Palomero, Julia Perez Baz, Rosa Fernandez Chimeno, Antonio Medarde Fernandez, Librada Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
-
Publication number: 20090124686Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.Type: ApplicationFiled: July 28, 2006Publication date: May 14, 2009Applicant: NEUROPHARMA, S.A.Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
-
Publication number: 20090069430Abstract: The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.Type: ApplicationFiled: June 16, 2008Publication date: March 12, 2009Applicant: NEUROPHARMA, S.A.Inventors: Ana MARTINEZ GIL, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Laura Rubio Arrieta, Esther Garcia Palomero, Celia De Austria De Luque, Jorge Sanchez-Quesada, Daniel Ignacio Perez Fernandez, Javier Lopez Ogalla, Diana Alonso Gordillo
-
Publication number: 20080275088Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.Type: ApplicationFiled: July 28, 2006Publication date: November 6, 2008Applicants: NEUROPHARMA, S.A., INSTITUTO BIOMAR, S.A.Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
-
Publication number: 20080153886Abstract: The invention relates to the use of heterocyclic compounds in the preparation of a medicament for regenerating damaged neuronal tissue. According to a preferred embodiment, formula I compounds are used to produce a medicament for regenerating neuronal tissue in pathologies or conditions that involve neuronal damage or death in the central nervous system or peripheral nervous system.Type: ApplicationFiled: February 10, 2006Publication date: June 26, 2008Applicant: NEUROPHARMA, S.A.Inventors: Ana Martinez Gil, Rosario De Luna Medina, Ana Perez Castillo, Mercedes Alonso Cascon
-
Publication number: 20070088080Abstract: The present invention provides the use of a compound of formula (I); wherein: n is 0, 1, 2, or 3, the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds; R, and R?are independently selected from hydrogen, alkyl, aryl, —OH, —OR? —SH, —SR?—NH, —NHR?, ?O, ?NH, ?NR?; R? is independently selected from alkyl, aryl, in the preparation of a medicament for the treatment of a disease requiring a GSK-3 inhibitor. Also provided is a compound of formula (II); wherein n is 0, 1, 2, or 3 the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds. Also provided are methods of treating chronic neurodegenerative conditions.Type: ApplicationFiled: December 2, 2004Publication date: April 19, 2007Applicant: NEUROPHARMA, S.A.Inventors: Diana Gordillo, Isabel Diaz, Ana Martinez-Gil, Gema Del Pliego, Ana Huerta, Ma Jose Puerto, Ester Aparicio, Dario Navarro, Miguel Padilla
-
Publication number: 20050222220Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.Type: ApplicationFiled: April 5, 2005Publication date: October 6, 2005Applicant: NEUROPHARMA, S.A.Inventors: Miguel Padilla, Mercedes Cascon, Isabel Diaz, Ana Gil, Gema del Pliego, Ana Huerta, Maria Puerto